Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 4/2011

01-08-2011 | Editorial

Targeting bone metastases starting from the preneoplastic niche: home sweet home

Authors: Daniele Santini, Bruno Vincenzi, Francesco Pantano, Giuseppe Tonini, Francesco Bertoldo

Published in: Breast Cancer Research | Issue 4/2011

Login to get access

Abstract

The metastatic process is a multistep coordinated event with a high degree of efficiency. Specific subpopulations of cancer stem cells, with tumor-initiating and migratory capacity, can selectively migrate towards sites that are able to promote survival and/or proliferation of metastatic tumor cells through a microenvironment modification. Cross-talk between the bone microenvironment and cancer cells can facilitate bone tropism of cancer cells. Fully understanding this complexity represents a major challenge in anti-cancer research and a mandatory step towards the development of new drugs potentially able not only to reduce the consequences of bone lesions but also to target the metastatic process in visceral sites.
Literature
1.
2.
Grimm J, Grimm W: The Complete Grimm's Fairy Tales. 1944, New York: Pantheon Books
3.
Pardal R, Clarke MF, Morrison SJ: Applying the principles of stem-cell biology to cancer. Nat Rev Cancer. 2003, 3: 895-902. 10.1038/nrc1232.CrossRefPubMed
4.
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003, 100: 3983-3988. 10.1073/pnas.0530291100.CrossRefPubMedPubMedCentral
5.
Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S, Lyden D: VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005, 438: 820-827. 10.1038/nature04186.CrossRefPubMedPubMedCentral
6.
Ramaswamy S, Perou CM: DNA microarrays in breast cancer: the promise of personalised medicine. Lancet. 2003, 361: 1576-1577. 10.1016/S0140-6736(03)13322-3.CrossRefPubMed
7.
Shimoyama A, Wada M, Ikeda F, Hata K, Matsubara T, Nifuji A, Noda M, Amano K, Yamaguchi A, Nishimura R, Yoneda T: Ihh/Gli2 signaling promotes osteoblast differentiation by regulating Runx2 expression and function. Mol Biol Cell. 2007, 18: 2411-2418. 10.1091/mbc.E06-08-0743.CrossRefPubMedPubMedCentral
8.
Gerritsen ME, Soriano R, Yang S, Ingle G, Zlot C, Toy K, Winer J, Draksharapu A, Peale F, Wu TD, Williams PM: In silico data filtering to identify new angiogenesis targets from a large in vitro gene profiling data set. Physiol Genomics. 2002, 10: 13-20.CrossRefPubMed
9.
Santini D, Perrone G, Roato I, Godio L, Pantano F, Grasso D, Russo A, Vincenzi B, Fratto ME, Sabbatini R, Della Pepa C, Porta C, Del Conte A, Schiavon G, Berruti A, Tomasino RM, Papotti M, Papapietro N, Onetti Muda A, Denaro V, Tonini G: Expression pattern of receptor activator of NFκB [RANK] in a series of primary solid tumors and related bone metastases. J Cell Physiol. 2011, 226: 780-784. 10.1002/jcp.22402.CrossRefPubMed
10.
Santini D, Schiavon G, Vincenzi B, Gaeta L, Pantano F, Russo A, Ortega C, Porta C, Galluzzo S, Armento G, La Verde N, Caroti C, Treilleux I, Ruggiero A, Perrone G, Addeo R, Clezardin P, Muda AO, Tonini G: Receptor activator of NF-kB [RANK] expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One. 2011, 6: e19234-10.1371/journal.pone.0019234.CrossRefPubMedPubMedCentral
Metadata
Title
Targeting bone metastases starting from the preneoplastic niche: home sweet home
Authors
Daniele Santini
Bruno Vincenzi
Francesco Pantano
Giuseppe Tonini
Francesco Bertoldo
Publication date
01-08-2011
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 4/2011
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2911

Other articles of this Issue 4/2011

Breast Cancer Research 4/2011 Go to the issue

Viewpoint

Cannibalism, cell survival, and endocrine resistance in breast cancer

Review

Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment

Viewpoint

Estrogen receptor degradation: a CUE for endocrine resistance?

Review

Choosing the right cell line for breast cancer research

Research article

Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study

Research article

NF-kappaB activation within macrophages leads to an anti-tumor phenotype in a mammary tumor lung metastasis model
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits